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ABSTRACT
GH has many biological roles, including promotion of growth. Most,
if not all, of its roles are achieved through interaction with its receptor.
We chose to study the effects of loss of GH signaling on growth and
aging in a mouse model for Laron Syndrome (LS) in which the
GHR/BP gene has been disrupted. We observed that mice homozygous
for the disruption (2/2) were significantly smaller than normal wild-
type (1/1) mice as well as mice heterozygous for the disruption, even
at 1.5 yr of age. IGF-I levels were also significantly lower in the 2/2
mice and remained low as the mice aged. IGFBP-3 levels were se-
verely reduced in the 2/2 mice, whereas IGFBP-1, -2, and -4 levels
remained unchanged. Finally, the 2/2 mice lived significantly longer
than 1/1 and 1/2 mice. The latter result contradicts the anti-aging
GH data and suggests the need for further analysis of GH and aging.
(Endocrinology 141: 2608–2613, 2000)
GH IS A protein produced and secreted by a set of spe-cialized cells in the anterior pituitary. GH has direct and
indirect effects on many tissues, such as stimulating bone and
soft tissue growth and influencing carbohydrate, protein, and
lipid metabolism. Direct biological activities of GH include re-
ceptor binding, internalization of the hormone/receptor com-
plex, and activation of proteins involved in signal transduction
(for recent reviews, see Refs. 1, 2, 3).
Protein and RNA transcripts for receptors of GH (GHR)
have been detected in many of the tissues influenced by the
hormone (4–7). It was determined that a single molecule of
GH binds sequentially to two receptor molecules, forming an
active complex (8). This complex, in turn, signals stimulation
of other genes, including insulin-like growth factor I (IGF-I).
IGF-I, produced and secreted by the liver and other target
tissues, mediates some of the indirect effects of GH on
growth and development (9, 10). Other intracellular events
occurring after the GH/GHR interaction include activation
of tyrosine kinases such as Janus kinase 2 (Jak-2), which leads
to phosphorylation and activation of other proteins includ-
ing signal transducer and activator of transcription 5A (STAT
5A) and mitogen activated protein (MAP) kinase that, in
turn, activate other proteins and genes (2, 11).
The cDNA encoding the GHR has been cloned from many
species (5, 6). The receptor consists of an extracellular hor-
mone-binding region (exons 2–7), a single membrane span-
ning region (exon 8), and an intracellular region (exons 9–10)
(12). GHR has no intrinsic kinase domain, but the intracel-
lular region plays a major role in the signal transduction
process (13). A truncated form of the receptor, known as GH
binding protein (GHBP), lacks the transmembrane and in-
tracellular regions of GHR and is secreted into the serum (14).
The truncated protein is produced by one of two different
processes, depending on the animal species. In mice and rats,
alternative splicing of GHR precursor messenger RNA re-
places the transmembrane and intracellular regions with a
very short hydrophilic tail (encoded by exon 8A; 15, 16). In
humans, cows, and pigs (among others), no alternative RNA
splicing is apparent but instead the GHBP is produced by
proteolysis of the GHR (17). The function of the binding
protein is not clear, but it appears to modulate the level of
circulating GH (18).
In an attempt to understand the actions of GH, an animal that
is resistant to GH action would be of value. Previously, we
generated GH resistant animals by expression of a GH antag-
onist gene in transgenic mice (19–22). These mice are smaller
than control mice, with reduced levels of IGF-I. They also are
resistant to diabetes-induced end organ damage (23). In an
alternative approach, we disrupted the mouse GHR/BP gene,
mimicking the primary defect causing Laron syndrome in hu-
mans (24). Mice homozygous for the gene disruption are
smaller in size with reduced levels of IGF-I but increased levels
of GH. We have recently demonstrated that these mice are also
resistant to diabetes-induced end organ damage (25).
One question that has remained controversial is the role of
GH in aging. It has been reported that dwarf mice deficient
in GH have longer life expectancies (26). However, the mice
used in those studies also had other hormonal deficiencies.
We have extended our initial investigations to assess the
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combined effects of the GHR/BP gene disruption and ad-
vancing age on weight gain, IGF-I and IGF binding protein
(IGFBP) levels, and longevity.
Materials and Methods
Animals
The mice used in this study were derived from a founder created by
deletion and gene substitution of most of the fourth exon and part of the
fourth intron of the GHR/BP gene (24). Their genetic background was
a mix of 129Ola and BalbC. Nontransgenic (1/1), heterozygous (1/2)
and homozygous (2/2) progeny were generated by 1/2 3 1/2
matings and genotyped after weaning by PCR (27). The mice were ear
notched for identification purposes, housed in groups of mixed geno-
type of up to four mice per cage, provided with standard rodent chow
(26%, 14%, and 60% of the calories were provided by protein, fat and
carbohydrates, respectively; 5P00 Prolab RMH 3000, PMI Nutrition In-
ternational, Inc., Brentwood, MO) and water ad libitum, and maintained
on a 14-h light, 10-h dark cycle. All procedures were approved by Ohio
University’s Institutional Animal Care and Use Committee and com-
plied with federal, state, and local laws.
Weight gain profiles
Progeny of multiple 1/2 3 1/2 matings were weighed at weekly
intervals starting at weaning (four weeks of age). Mean weights for each
mouse were calculated at 4-week intervals (termed weighing intervals) for
statistical analysis. Thus, mice averaged 5.5 weeks of age for weighing
interval 1, 9.5 weeks of age for weighing interval 2, etc. Means of the
weighing interval means were determined and plotted for each gender
(male and female) and genotype (1/1, 1/2, 2/2). One 2/2 male was
excluded from the final analysis since his weight differed from the mean
by greater than 2 standard deviations (sd) from the age of 5 weeks onward.
Plasma IGF-I measurements
Blood was collected into heparinized tubes from the tails of five mice
of each gender (male and female), genotype (1/1, 1/2, and 2/2), and
age (averaging 1, 10 and 23 months). After centrifugation, the plasma
was transferred to a new tube and stored at 220 C. IGFBPs were re-
moved from duplicate samples using an acid-ethanol extraction kit
essentially as described by the manufacturer (Nichols Institute Diag-
nostics, San Juan Capistrano, CA) except that extractions were scaled
down 20-fold and the total dilution for samples from 2/2 mice was only
25-fold, whereas the total dilution for samples from 1/1 and 1/2 mice
was the standard 225-fold. These changes were necessary due to the
reduced body size and, thus, reduced blood volume of the 2/2 mice
as well as due to the extremely low levels of IGF-I in the 2/2 mice. Tests
were performed to ensure that the results were not altered by the
changes. IGF-I levels were measured using a human IGF-I RIA kit with
human IGF-I standards (Nichols Institute Diagnostics, San Juan Cap-
istrano, CA). Values between assays were normalized by use of two
control plasma samples included in each assay. Means were determined
for each gender, genotype and age.
Plasma IGFBP analysis
Blood was collected into heparinized tubes from the tails of 60-day-
old male and female 1/1, 1/2 and 2/2 mice. After centrifugation, the
plasma was transferred to a new tube and stored at 220 C. IGFBP levels
were assessed by ligand blotting (28) and quantified by scanning den-
sitometry (29).
Longevity analysis
An average lifespan was calculated for 1/1, 1/2 and 2/2 male
and female mice using mice born between July and December of 1996
that had spontaneously died.
Statistical analyses
Weights at specific time points or as differences between two time
points, as well as lifespans, initially were analyzed by two-way (geno-
type 3 gender) ANOVA using Quick Statistica for Macintosh (StatSoft;
Tulsa, OK). IGF-I levels initially were analyzed by three-way (geno-
type 3 gender 3 age) ANOVA. As no statistically significant interac-
tions (P , 0.05) were observed, significant main effects of independent
variables were analyzed by one-way ANOVA followed by posthoc
comparisons using Tukey’s HSD test, collapsing across the other inde-
pendent variable(s) when it was not differing significantly or separately
when it was differing significantly. Student’s t test for nonpaired sam-
ples was used to assess age of attainment of final weight and also
IGFBP-3 levels.
Results
GHR/BP 2/2 mice grow more slowly and remain
significantly smaller than their 1/1 and 1/2 littermates
Growth, as assessed by weight gain, is dramatically dif-
ferent in GHR/BP gene-disrupted 2/2 mice as compared
with 1/1 and 1/2 mice (Figs. 1 and 2). At 4 weeks of age,
which was when the pups were weaned and this study
initiated, weights did not differ significantly between gen-
ders or between 1/1 and 1/2 mice, but 2/2 mice weighed
significantly less than 1/1 mice (;45% less; P , 0.0002).
To assess rates of growth immediately after weaning, the
weight differences between weighing intervals 1 and 2 (a
4-week increase in age) were analyzed (Fig. 2). Significant
differences were seen between male and female 1/1 mice
(P , 0.004) and male and female 1/2 mice (P , 0.02), but
not between male and female 2/2 mice, indicating a loss of
gender difference in the 2/2 mice. For both genders, the
rates of growth for 1/1 and 1/2 mice did not differ, but
the 2/2 mice grew significantly slower (P , 0.0002).
Although they have a slower rate of growth, it might be
expected that the 2/2 mice eventually attain a final weight
similar to 1/1 mice but that it just takes longer. However,
FIG. 1. Size comparison of GHR/BP gene disruption littermates.
Three female mice from the same litter were photographed at 5
months of age to show their differences in size. Left, Normal genotype
(1/1). Middle, Homozygous for the GHR/BP gene disruption (2/2).
Right, Heterozygous for the GHR/BP gene disruption (1/2).
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this was not observed. In fact, 2/2 mice reached their max-
imum weight at an earlier age than did the 1/1 and 1/2
mice (Fig. 2). Male 2/2 mice reached their maximum weight
at weighing interval 3 (an average age of 14 weeks), whereas
male 1/1 mice reached their maximum weight 28 weeks
later (weighing interval 10). Female 2/2 mice reached their
maximum weight at weighing interval 8 (an average age of
34 weeks), whereas female 1/1 mice reached their maxi-
mum weight 12 weeks later (weighing interval 11). Het-
erozygous mice reached plateaus at weighing interval 8 for
males and weighing interval 11 for females. The maximally
attained weights, analyzed at weighing interval 20, did not
differ significantly between genders or between 1/1
and 1/2 mice, but 2/2 mice were significantly smaller (P ,
0.0002), attaining a final weight that was approximately 40%
that of 1/1 mice.
IGF-I levels remain significantly lower in GHR/BP 2/2
mice than in 1/1 and 1/2 mice
As indicated by the decrease in body size, GHR/BP gene-
disrupted 2/2 mice of both genders have severely reduced
levels of plasma IGF-I, measured at less than 10% the levels
found in 1/1 mice (Fig. 3). A small but significant difference
between 1/1 and 1/2 mice was also observed (P , 0.005),
mainly driven by the difference in levels at 10 months of age.
There were no significant differences seen between genders or
with age, although there was a slight tendency for 1/1 levels
to decrease and 2/2 levels to increase at the 23-month time
point.
IGFBP-3 levels are severely reduced in GHR/BP 2/2 mice
Because IGF-I levels were dramatically affected in the
GHR/BP gene-disrupted 2/2 mice, IGFBP profiles were
also assessed (Fig. 4 and Table 1). As no significant changes
in IGF-I levels were seen at different ages for the gene-
disrupted mice, the IGFBP profile was examined at a single
age of 60 days. Ligand blotting using radiolabeled IGF-I
revealed no changes in plasma levels of IGFBP-1, IGFBP-2,
and IGFBP-4 in 60-day-old mice, but a severe reduction in
IGFBP-3 levels was detected in male and female 2/2 mice
(Fig. 4). Scanning densitometry of the IGFBP profiles indi-
cated an approximately 20-fold decrease in IGFBP-3 levels in
2/2 mice in comparison to 1/1 mice (P , 0.001; Table 1).
FIG. 2. Weight gain profiles for the various GHR/BP gene-disrupted mice. Means derived from weekly weights averaged at 4-week intervals
were plotted for each genotype and gender.
FIG. 3. Plasma IGF-I concentrations determined at three different
ages. IGF-I concentrations were measured by RIA after acid-ethanol
extraction of plasma from five mice of each indicated gender, genotype
and age. Top panel, Males. Bottom panel, Females.
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Levels of IGFBPs, including IGFBP-3, in 1/2 mice were
similar to 1/1 mice and thus were not extensively analyzed.
GHR/BP 2/2 mice live longer than their 1/1 and 1/2
littermates
Because a decreased body size has been suggested to result
in a longer lifespan (26), average lifespans were calculated for
each genotype and gender to assess longevity in the GHR/BP
gene-disrupted mice (Table 2). Statistical analysis indicated
that males and females had similar lifespans. There were also
no differences in lifespans of 1/1 and 1/2 mice, but a
significant increase in lifespan of nearly a year was observed
for 2/2 mice (P , 0.0002). Thus, loss of one GHR/BP allele
had no effect on lifespan but loss of both GHR/BP alleles
resulted in a significant extension of lifespan, regardless of
gender.
Discussion
Until creation of the GHR/BP gene-disrupted mouse,
studies investigating the effects of lack of GH signaling em-
ployed mainly hypophysectomized animals or genetic
dwarfs such as the Ames, Snell, or little (lit/lit) mice. Of these
models, only the lit/lit mouse exhibited isolated GH defi-
ciency with no alteration in the levels of the other pituitary
hormones. One study involving the lit/lit mouse examined
several parameters over the course of a year (30). As was seen
in the GHR/BP 2/2 mice in the present study, serum IGF-I
levels were extremely low in the lit/lit mice throughout the
time period examined. Likewise, expression of IGFBP-3,
which is regulated by GH, was severely reduced while ex-
pression of the other IGFBPs remained unaffected. Curi-
ously, there was a difference in weight gain between the
lit/lit mice and the GHR/BP 2/2 mice. While the mean
weights of the male and female GHR/BP 2/2 mice leveled
out at approximately 15 g, the mean weights of the male
lit/lit mice continued to increase such that the lit/lit males
caught up with 1/lit female controls (24 g). This additional
weight gain in the lit/lit mice appeared to be due to an
increased accumulation of fat. Although a few obese
GHR/BP 2/2 mice have been seen in our colony, this does
not appear to be the norm.
Even though in previous experiments we had shown little
difference between GHR/BP 1/1 and 1/2 mice (24), we
included the 1/2 mice in our present study to characterize
them more extensively. Once again, in all the parameters
tested, there was little difference between 1/1 and 1/2
mice. This further supports the observation that only one
functional GHR/BP allele is necessary for full GHR/BP
activity.
An area of study that has received limited attention in iso-
lated GH-deficient animal models is an assessment of longevity.
Alterations in longevity, or life expectancy, cannot easily be
assessed in humans, but this is not the case in mice. We show
here that the lifespan of 2/2 mice is significantly increased in
comparison to 1/1 and 1/2 mice. This analysis is the first
documented study of life expectancy in animals or humans
with mutations that cause isolated GH deficiency or altered/
disrupted GH signaling. These results are in agreement with the
increased longevity seen in hypophysectomized rats that were
provided replacement therapy with glucocorticoids or thyrox-
ine and seen in Ames and Snell dwarf mice as well as humans
that are deficient in GH, PRL, and TSH (reviewed in Refs. 26 and
31). The results implicate GH deficiency as the major factor in
increased longevity and suggest use of a cautionary approach
FIG. 4. Plasma IGFBP profiles for the GHR/BP gene-disrupted mice.
Plasma from 60-day-old GHR/BP gene-disrupted mice and their con-
trols were analyzed for IGFBPs by ligand blot. Top panel, Males.
Bottom panel, Females. Lanes 1 and 2, Normal genotype (1/1). Lanes
3 and 4, Heterozygous genotype (1/2). Lanes 5 and 6, Homozygous
genotype (2/2). Molecular weight standards are shown on the left,
Mr 3 10
23. The arrows on the right indicate, from top to bottom
respectively, the positions of IGFBP-3 (double bands), IGFBP-1 and
-2 (double bands), and IGFBP-4 (single band).
TABLE 1. Scanning densitometry values for IGFBP-3
Gender Genotype N Scanning unitsa
Males 1/1 7 5512 1/2 164
2/2 7 210 1/2 72b
Females 1/1 7 6125 1/2 492
2/2 6 310 1/2 44b
a Mean 6 SE.
b P , 0.001 compared with 1/1.
TABLE 2. Analysis of lifespan in GHR/BP gene-disrupted mice
Gender Genotype N Lifespan (days)a
Males 1/1 7 629 1/2 72
1/2 8 668 1/2 51
2/2 7 975 1/2 106b
Females 1/1 13 749 1/2 41
1/2 19 701 1/2 36
2/2 11 1031 1/2 41c
a Mean 6 SE.
b P , 0.01 compared with 1/1.
c P , 0.0002 compared with 1/1.
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to the therapeutic administration of GH, especially as an anti-
aging agent, until more studies can be completed.
Although the GHR/BP 2/2 mice appear to have a longer
life expectancy, it is not clear whether they have a prolonged
senescence or whether their entire development proceeds
more slowly. We had previously observed that the first con-
ception was somewhat delayed in matings between
GHR/BP 2/2 males and females (24). Danilovich et al. (32)
further examined the GHR/BP 2/2 females and found that
their sexual maturity was delayed by approximately one
week. These results suggest that the GHR/BP 2/2 mice may
age more slowly than their 1/1 counterparts, but this hy-
pothesis needs to be further tested.
While the mechanism of aging remains elusive, one aging
theory purports that exposure to growth factors and the rate
of decline in reserve capacity influence lifespan (33). Support
of this comes from caloric restriction studies in mammals,
which result in decreased exposure to growth stimulus (e.g.
GH, IGF-I, and insulin) and an increase in lifespan (33). At
the molecular level, in addition to the GHR/BP gene dis-
ruption results presented here, two other genes have been
identified that suggest involvement of the GH signaling
pathway in determination of lifespan. daf-2, an insulin
receptor-like gene from Caenorhabditis elegans, controls
growth in a manner that may be homologous to the mam-
malian IGF-I receptor that acts downstream of GHR in the
GH signaling pathway (34). Mutation of daf-2 results in a
marked increase in longevity (34). To distinguish direct ef-
fects of GH from effects of IGF-I, it would be interesting to
add back IGF-I to the GHR/BP 2/2 mice, either genetically
or by IGF-I administration, and assess the effect on aging. In
another report, gene disruption of the p66shc gene in mice
results in an increased lifespan (35). It also enhances resis-
tance to environmental stresses such as UV light and reactive
oxygen species (35). The authors cite an expanding list of
references that suggest a correlation between enhanced re-
sistance to environmental stresses and an extended lifespan.
It is of interest to note that GH regulates the phosphorylation
status of two other SHC proteins, p52shc and p46shc (36). If
disruption of either of these genes also resulted in enhanced
resistance to environmental stresses, the same could hold
true for disruption of the GHR/BP gene and GH signaling.
Testing the resistance of the GHR/BP gene-disrupted mice
to environmental stress would support or refute this idea.
In summary, disruption of the gene for GHR/BP results in
2/2 mice that are significantly smaller than their 1/1
and 1/2 littermates. This difference, as assessed by weight
gain, as well as their IGF-I levels, remains constant well into
old age. IGFBP-3 levels are also significantly reduced in the
GHR/BP 2/2 mice. Despite, or perhaps as a result of, their
decreased growth, GHR/BP 2/2 mice have a longer life
expectancy. Further experiments are in progress to elucidate
the role of GH in aging.
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